Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AbbVie's Alzheimer's Efforts Voyage Into AAV-Targeted Tau Antibodies

Executive Summary

Collaboration between Voyager and AbbVie will attempt to produce a single-administration gene therapy targeting tau protein, using adeno-associated vector technology to pass the blood-brain barrier.

Related Content

AbbVie Explores Uncharted Territory With DUB Inhibitor Neuroscience Deal
AbbVie, Calico Extend Their Collaboration On Aging
Biopharma Quarterly Dealmaking Statistics, Q1 2018
Deal Watch: Fresenius Buyout Of Akorn Potentially Threatened By Data Integrity Issues
Voyager Cheers End Of Sanofi Partnership In Parkinson's; Investors Less Confident
AbbVie Goes Boldly Into Immuno-Neurology With Alector
Sanofi-Backed Voyager Therapeutics Hails Gene Therapy's Arrival
Biogen Builds In Neurodegenerative Disease With Anti-Tau Deal
Genzyme commits $100m upfront for Voyager's gene therapy expertise in CNS


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts